TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02155946

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial direct current stimulation (tDCS) Soterix Medical Inc. tDCS unit
Description: Active brain stimulation

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial direct current stimulation (tDCS) Soterix Medical Inc. tDCS unit
Description: Active brain stimulation

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial direct current stimulation (tDCS) Soterix Medical Inc. tDCS unit
Description: Sham (placebo)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial direct current stimulation (tDCS) Soterix Medical Inc. tDCS unit
Description: Sham (placebo)
Study: NCT00762593

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: transvaginal placebo device
Description: Use of a transvaginal placebo home use programmable device used 30 minutes every day during 8 weeks

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transvaginal electrical stimulation device
Description: Use of a transvaginal electrical stimulation home use programmable device used 30 minutes every day during 8 weeks
Study: NCT02281097

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Stimulation
Description: Application of current to skin above auricular branch of vagal nerve to modulate heart rate and symptoms

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Stimulation
Description: Application of current to skin above auricular branch of vagal nerve to modulate heart rate and symptoms

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Application of low intensive current or frequency to skin above auricular branch of vagal nerve as sham intervention

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Application of low intensive current or frequency to skin above auricular branch of vagal nerve as sham intervention
Study: NCT00706849

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mipomersen sodium
Description: 200 mg /mL

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 1 mL matching placebo
Study: NCT03249688

Intervention type: OTHER
Group type: OTHER
Intervention: Regular health advice
Description: Routine healthy lifestyle counseling

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multidomain lifestyle
Description: Nutritional guidance, exercise, cognitive training, vascular risk monitoring

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multidomain lifestyle
Description: Nutritional guidance, exercise, cognitive training, vascular risk monitoring

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Medical food
Description: Medical food product (Fortasyn Connect)
Study: NCT03590431

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: extrinsic iodine in milk
Description: 300 ml whole cow's milk delivering ≈ 200 µg iodine (extrinsic iodine, low protein-bound fraction) The whole cow's milk will be produced in an experimental barn feeding supplementary iodine to reach a final iodine concentration of ≈ 50 µg/L. The iodine content of the extrinsically labelled milk will be adjusted to the required concentration (same as intrinsic iodine milk) by adding iodine in form of potassium iodide.

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: intrinsic iodine in milk
Description: 300 ml whole cow's milk delivering ≈ 200 µg iodine (intrinsic iodine, high protein-bound fraction) The whole cow's milk will be produced in an experimental barn feeding supplementary iodine to reach a final iodine concentration of ≈ 600 µg/L. This concentration will define final supplemental iodine given to the participants (adapting the total portion size).

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: water iodine solution
Description: 300 ml water delivering ≈ 200 µg iodine (control)
Study: NCT02614066

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: brexucabtagene autoleucel
Description: A single infusion of brexucabtagene autoleucel CAR transduced autologous T cells administered intravenously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Administered intravenously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Administered intravenously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Administered intravenously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Administered intravenously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Administered intravenously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Administered intravenously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Administered intravenously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Administered intravenously.
Study: NCT01666613

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD8683
Description: Solution for injection, administered as intravenous infusion Total dose of 100µg AZD8683

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD8683
Description: Solution to be administered orally Total dose of 950 µg AZD8683

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD8683
Description: Dry powder inhaled via New Dry Powder Inhaler, 540 µg delivered dose AZD8683

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD8683
Description: Dry powder inhaled via Turbuhaler™, 600 µg delivered dose AZD8683
Study: NCT00600782

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK Biologicals' Candidate Tuberculosis (TB) Vaccine (692342)
Description: Intramuscular injection, 2 doses at 0, 1 month
Study: NCT01249443

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vorinostat
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: diagnostic laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: Given IV
Study: NCT02273466

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Desipramine tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desipramine tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Crobenetine infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo infusion
Study: NCT00881244

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AS1411
Description: I.v. 4-7 days, 1-40 mg/kg/day
Study: NCT03053999

Intervention type: OTHER
Intervention: Genome Sequencing
Description: Analyses includes genome sequencing based analysis to identify novel germline variations in blood DNAs and somatic changes in tumor DNAs, which may contribute to the development of pancreatic tumors.

Intervention type: OTHER
Intervention: Data Review
Description: Clinical information retrieved from the patients' medical record including: de-identified demographic data (age, gender, race/ethnicity), medical history, family history, disease status, treatment response, survival information, and selected clinical data from medical record (calcium levels, calcitonin levels).
Study: NCT02027194

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cure-Allergic Rhinitis Syrup
Description: Delivered one bottle for two weeks to the participants twice

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Yu-ping-fung San
Description: Delivered one bottle for 2-week usage to the participants twice

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Delivered one bottle (wheat power with favors) for 2-week usage to the participants twice
Study: NCT02167360

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CTL019
Description: A dose of CTL019 transduced cells will consist of a single infusion of 2 to 10 x 108 CTL019 transduced cells.
Study: NCT04214236

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ciNPT group
Description: Closed-incision negative pressure therapy (ciNPT) will be applied for 7 day using continuous suction at 125 mmHg. To deliver ciNPT we will use a commercially available, FDA-approved device, used according to the manufacturer' indications (PREVENA™ Incision Management System (KCI, San Antonio, Texas, USA). After the first 7 post-operative days, subjects will discontinue the ciNPT and follow a standard wound care protocol.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Control group
Description: Standard non-adherent surgical dressing (Vaseline petrolatum gauze) will be used for management of incisional wounds in the control group. Dressing changes will be performed per standard wound care protocol.
Study: NCT03294655

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pilot Resilience Building Intervention
Description: The intervention will include a brief one-on-one visit in which psychoeducational information on building resilience will be given via a PowerPoint presentation, which will include exercises for the participants to engage in over the following four weeks in their daily lives. After the presentation participants will also develop a personalized intervention plan where they will choose at least five areas of the American Psychological Association 10 Strategies for Building Resilience on which to specifically focus. Participants will also receive a pamphlet of abbreviated information from the PowerPoint presentation.
Study: NCT03120923

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine 3 cc

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine 9 cc
Description: 9mL of 1% lidocaine plus 1mL of 40mg triamcinolone acetonide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triamcinolone Acetonide

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triamcinolone Acetonide
Study: NCT02423720

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Audio-Based Mindfulness
Description: Audio-based mindfulness tracks (MP3 format).
Study: NCT03020082

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Danoprevir
Description: Danoprevir (DNV)administered orally 100mg BID for 12 weeks;

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir
Description: Ritonavir administered orally 100mg BID for 12 weeks;

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: peginterferon alfa-2a
Description: PEG-IFN abdominal or thigh subcutaneous injection, 180μg, once a week for 12 weeks;

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RBV
Description: RBV administered orally 500mg (5 tablets)( body weight \<75Kg) BID, 600mg (6 tablets) BID body weight ≥75Kg, for 12 weeks.
Study: NCT04169659

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Kyphoplasty with insertion of Sctructured Titanium Microspheres
Description: Under fluoroscophy, we introduce a transpeduncolar trocar inside the vertebral body where is performed a kyphoplasty with insertion of baloons. When the dome is cretated we introduce structured titanium microspheres until the dome is full of material.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Kyphoplasty with Polimethylmetacrilate (convetional surgery)
Description: Under fluoroscophy, we introduce a transpeduncolar trocar inside the vertebral body where is performed a kyphoplasty with insertion of baloons. When the dome is cretated we introduce Polimethylmetacrilate until the dome is full of material.
Study: NCT00003474

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antineoplaston therapy (Atengenal + Astugenal)
Description: Adults with a residual/recurrent/progressive Glioblastoma Multiforme will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1.
Study: NCT04674800

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MYL-1701P, a proposed biosimilar to Eylea
Description: Open label and single arm
Study: NCT02644811

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topical anesthesia (buccal and palatal)
Description: Saliva is removed with a sterile swab followed by application of 5% Lidocaine gel (APL, Sweden) on the gingiva.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topical anesthesia (buccal and palatal)
Description: Saliva is removed with a sterile swab followed by application of 5% Lidocaine gel (APL, Sweden) on the gingiva.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Local anesthesia (buccal and palatal)
Description: Injection of 1,5 ml Xylocaine Dental Adrenaline (Lidocaine hydrochloride 20 mg/ml, adrenaline 12.5 µg/ml, Dentsply Pharmaceutical, Weybridge, Surrey, UK).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Local anesthesia (buccal and palatal)
Description: Injection of 1,5 ml Xylocaine Dental Adrenaline (Lidocaine hydrochloride 20 mg/ml, adrenaline 12.5 µg/ml, Dentsply Pharmaceutical, Weybridge, Surrey, UK).

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Extraction of the maxillary first premolars
Description: Careful extraction of the maxillary first premolars after mobilization.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Extraction of the maxillary first premolars
Description: Careful extraction of the maxillary first premolars after mobilization.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topical anesthesia (buccal)
Description: Saliva is removed with a sterile swab followed by application of 5% Lidocaine gel (APL, Sweden) on the gingiva.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Local anesthesia (buccal)
Description: Injection of 0.3 ml Xylocaine Dental Adrenaline (Lidocaine hydrochloride 20 mg/ml, adrenaline 12.5 µg/ml, Dentsply Pharmaceutical, Weybridge, Surrey, UK).

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Molarblock
Description: Molarblock is a Stainless steel ligature connecting the maxillary second premolar with the maxillary first and second molar.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Spider Screw K1 short neck
Description: The Spider Screw K1 (Health Development Company, Sarcedo, Italy) is a self-drilling and self-tapping screw. Short neck screws (SCR-1508 and SCR-1510) with a diameter of 1.5 mm and length 8 or 10 mm are used.
Study: NCT00362609

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pantoprazole

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pantoprazole
Study: NCT04566380

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ONO-4538
Description: IV infusion over 30 minutes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ONO-4538
Description: IV infusion over 30 minutes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin
Description: IV infusion over 2 hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-1
Description: Administered orally twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine
Description: Administered orally twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: IV infusion over 30 minutes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: temozolomide
Description: Administered orally once daily for 5 days every 28 days
Study: NCT03614988

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Evening Levothyroxine Administration
Description: Bedtime levothyroxine intake, with 60-minute meal-free interval

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Morning Levothyroxine Administration
Description: Morning levothyroxine intake, 60 minutes before breakfast.
Study: NCT04483232

Intervention type: BIOLOGICAL
Intervention: Ear canal swab
Description: Ear canal swab

Intervention type: BIOLOGICAL
Intervention: Ear canal swab
Description: Ear canal swab
Study: NCT04264195

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Constraint-induced movement therapy: PEPS-MIT
Description: All participants of control and experimental groups received standard stroke rehabilitation. After regular office time, a 2 hours' peer group session was provided, 5 days/week, 4 consecutive weeks, to both groups. One patient 'leads' the group exercises under a therapist's supervision. The therapist is mainly helping and correcting patients during the various exercise tasks.~• Specific for the experimental group was that patients performed all manipulation tasks with forced use of the paretic hand/arm by wearing a soft-padded mitten at the non-paretic hand, preventing manipulation with that hand. Patients were encouraged to wear the mitten also for 3 hours/day at home, while performing ADL and learned exercises. Behavioural strategies included a treatment contract and daily use of the home activity checklist which was checked by patient's caregiver and signed by both patient and caregiver. Each treatment day the activity checklist was submitted to the therapist who gives feedback.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Bimanual manipulation exercises (PEPS-Bimanual)
Description: All participants of control and experimental groups received standard stroke. After regular office time, a 2 hours' peer group session was provided, 5 days/week, 4 consecutive weeks, to both groups. One patient 'leads' the group exercises under a therapist's supervision. The therapist is mainly helping and correcting patients during the various exercise tasks.~Specific for the control group was that patients performed all manipulation tasks bimanually, as they used to do in occupational therapy activities. Patients were also asked to document their 'at home' activities in an activity checklist that was regularly checked by the therapists.
Study: NCT01250314

Intervention type: OTHER
Group type: OTHER
Intervention: Radiology
Description: Spine radiography, densitometry, evaluation of bone architecture and micro-architecture (computed tomography of lumbar spine and hip and peripheral micro-scanner (XREME SCANCO) at tibia and wrist).

Intervention type: OTHER
Group type: OTHER
Intervention: Radiology
Description: Spine radiography, densitometry, evaluation of bone architecture and micro-architecture (computed tomography of lumbar spine and hip and peripheral micro-scanner (XREME SCANCO) at tibia and wrist).

Intervention type: OTHER
Group type: OTHER
Intervention: Biological, biochemical and genetic samples
Description: \*Serum calcium and phosphore evaluation, bone remodeling markers, 25-hydroxyvitamin D level assessment: Blood samples plasma (5 ml):Creatin, calcemia, phosphoremia, alkaline phosphatase, bone alkaline phosphatase, osteocalcin, CTX, 25 hydroxyvitamin D and parathormone~Urinary samples :~Deoxy-pyridinoline, creatinuria Fasting morning urine on a sample Calciuria, creatinuria, cortisoluria Day urine on a sample~\*Assessment of possible determinants of fractures in man~Blood samples plasma (5 ml):~* Sexual Hormones: Estradiol, Testosterone, SHBG, LH, FSH~* Homocysteine~* IGF1~  * Extraction of DNA for a genetic polymorphism study:~Sample of 10 ml of blood on EDTA for DNA extraction.~Tested polymorphisms will be: LRP5, CYP19 (Aromatase), COL1A1 (Collagen I),MHTFR, IGF-1,VDR vitamin D receptor~Globally 20 ml of blood will be taken for each subject. Every biological sample for biochemical dosages and for genetic analysis will be preserved in an anonymous way.

Intervention type: OTHER
Group type: OTHER
Intervention: Biological, biochemical and genetic samples
Description: \*Serum calcium and phosphore evaluation, bone remodeling markers, 25-hydroxyvitamin D level assessment: Blood samples plasma (5 ml):Creatin, calcemia, phosphoremia, alkaline phosphatase, bone alkaline phosphatase, osteocalcin, CTX, 25 hydroxyvitamin D and parathormone~Urinary samples :~Deoxy-pyridinoline, creatinuria Fasting morning urine on a sample Calciuria, creatinuria, cortisoluria Day urine on a sample~\*Assessment of possible determinants of fractures in man~Blood samples plasma (5 ml):~* Sexual Hormones: Estradiol, Testosterone, SHBG, LH, FSH~* Homocysteine~* IGF1~  * Extraction of DNA for a genetic polymorphism study:~Sample of 10 ml of blood on EDTA for DNA extraction.~Tested polymorphisms will be: LRP5, CYP19 (Aromatase), COL1A1 (Collagen I),MHTFR, IGF-1,VDR vitamin D receptor~Globally 20 ml of blood will be taken for each subject. Every biological sample for biochemical dosages and for genetic analysis will be preserved in an anonymous way.
Study: NCT04281771

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: cardiac MRI
Description: Patients are studied on a clinical 1.5 Tesla scanner with cardiac radiofrequency receiver coil centered over the heart, and ECG monitoring. The following parameters are assessed:~Functional imaging: ECG-gated cine Steady-state free precession (SSFP) MRI images are obtained during repeated breath holds in long axis and short axis orientations covering the entire left ventricle. Global systolic and diastolic function are assessed, and left ventricular mass is calculated.~Flow imaging: ECG-gated 2D flow measurements are assessed above the prosthetic valve, and at the level of the pulmonary trunk.
Study: NCT00684138

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ACRYSOF® ReSTOR® Aspheric +4.0 D Add Power Intraocular Lens
Description: Intraocular Lens

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ACRYSOF® ReSTOR® Aspheric +3.0 D Add Power Intraocular Lens
Description: Intraocular Lens
Study: NCT03720171

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: e-OPRA Implant System
Description: Implantation of e-OPRA Implant System in lower limb to be used with amputation limb prosthesis
Study: NCT02355470

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: GIFTSS
Description: Universal education and brief counseling regarding sexual violence

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Brief alcohol use intervention
Description: Brief education and counseling intervention to promote safer alcohol use, reduce binge drinking
Study: NCT04303403

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib
Description: Taken orally once daily
Study: NCT04185272

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: analysis of BTN and BTNL status
Description: analysis of BTN and BTNL expression in colon cancer and hepatic metastasis

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: analysis of BTN and BTNL status
Description: analysis of BTN and BTNL expression in colon cancer and hepatic metastasis
Study: NCT00981773

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maraviroc
Description: Maraviroc 150 mg bid

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Maraviroc
Description: maraviroc 150 mg bid switch 12 weeks later
Study: NCT03945773

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabozantinib
Description: Oral tablets of 60mg, 40mg and 20 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabozantinib
Description: Oral tablets of 60mg, 40mg and 20 mg.